| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10342850 | SUN PHARM | Octreotide injection |
May, 2038
(14 years from now) | |
Bynfezia Pen is owned by Sun Pharm.
Bynfezia Pen contains Octreotide Acetate.
Bynfezia Pen has a total of 1 drug patent out of which 0 drug patents have expired.
Bynfezia Pen was authorised for market use on 28 January, 2020.
Bynfezia Pen is available in solution;subcutaneous dosage forms.
The generics of Bynfezia Pen are possible to be released after 15 May, 2038.
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 28 January, 2020
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
BYNFEZIA PEN family patents
